TCL Archive FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC. March 30, 2001
TCL Archive Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease December 28, 2012